|Founded||September 5, 1998(as BioPort Inc.)|
|Headquarters||Gaithersburg, Maryland, U.S.|
|Robert G. Kramer Sr. (CEO)|
Fuad El-Hibri (Executive Chairman of the Board of Directors)
|Revenue||US$1.11 billion (2019)|
Number of employees
|1,834 (February 14, 2020)|
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases, opioid overdoses, and provides medical devices for biodefense purposes. The company's gross revenue in 2018 was $782.4 million; gross income was $438.2 million; earnings before interest, taxes, depreciation, and amortization were $170.5 million.
Among the company's notable products are BioThrax (Anthrax Vaccine Adsorbed), the only anthrax vaccine licensed by the U.S. Food and Drug Administration (FDA) and Narcan (naloxone) for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
Fuad El-Hibri, the founder of the company and former CEO, led the company since its founding as BioPort Inc. until his retirement on April 1, 2012. El-Hibri continues to serve as the executive chairman of Emergent BioSolutions’ board of directors.
According to the U.S. National Library of Medicine, BioThrax was first made available in 1970. BioThrax (Anthrax Vaccine Adsorbed), a vaccine licensed by the U.S. Food and Drug Administration. Following a study by scientists from the Centers for Disease Control and Prevention, on December 19, 2008, Emergent received final FDA licensing for use of BioThrax five doses for intramuscular injection. Later in 2009, Emergent received approval from the FDA to extend the shelf life of its anthrax vaccine from three to four years.
BioThrax was approved for distribution in the United States in the US in 2015. BioThrax has received marketing approval in India, Singapore, and Germany. Health Canada, under the agency's Extraordinary Use New Drug Regulations, approved BioThrax for exclusive use against anthrax for an eight-year period. The Regulations provide a dual track for products allowing human usage while gathering clinical data on the effects of that usage. Additionally, the company has applied for approval of BioThrax in France, Poland, United Kingdom, Italy and the Netherlands.
The FDA gave BioThrax an "orphan drug" designation in April 2014. The FDA gives that status to drugs that are used to treat rare diseases. BioThrax is the only anthrax vaccine licensed by the FDA.
The main buyer of BioThrax is the U.S. Centers for Disease Control and Prevention (CDC). The CDC buys BioThrax for the Strategic National Stockpile (SNS). The government uses the SNS to protect the public in the event of a national emergency like a terrorist attack. As of December 2016, Emergent has a $911 million contract with the CDC for BioThrax. The BioThrax vaccines will go to the SNS. The contract will supply around 29.4 million doses of the vaccine. Additionally, the Biomedical Advanced Research and Development Authority (BARDA) released a notice of intent to purchase around $100 million of BioThrax for the SNS in 2017.
Emergent submitted an application to the FDA for use of a large facility in Lansing, Michigan to produce BioThrax. On June 21, 2016, Emergent announced that it had moved a step forward in the process: the FDA completed the pre-approval phase of its inspection.
The early 21st century set in motion the US Opioid Epidemic, "... the most serious and most important public health crisis today,” according to the Mayo Clinic Proceedings. Nasal spray naloxone, trade name “Narcan,” use has increased markedly during the opioid emergency. The epidemic is measured in overdose deaths, and also is seen in a downturn in overall health and the population's sense of well-being. Increased employment of naloxone such as Narcan among first responders and the public as a whole has reduced mortality, but recidivism is high. The US Opioid Epidemic has intensified the need for and continued use of Narcan to save those suffering from overdoses. The number of opioid deaths in the US doubled from 2010 to 2016 to 42,249 according to the FDA.
Narcan is mostly used as a “rescue drug” for individuals suffering from opioid overdose. Narcan, related to morphine, is an opioid antagonist that was originally synthesized and patented by Mozes J. Lewenstein and Jack Fishman in the US in 1961. The drug was patented in the UK by the Japanese company Sankyo (now Daiichi Sankyo). The US FDA approved the drug in treatment of opioid overdose in 1971.
In 2012, concerned about inconsistency of dosage, along with the need for a responder having some specialized training in making the naloxone injection in a tense, highly- charged emergency environment, Phil Skolnick, then director of the Division of Therapeutics & Medical Consequences at the National Institute on Drug Abuse and Roger Crystal, the chief executive officer of Lightlake Therapeutics (now Opiant Pharmaceuticals), teamed to develop an intranasal version of the drug. NIDA then generated a highly concentrated solution of naloxone which Lightlake was able to package in its nasal spray devices. After successful clinical trials, Lightlake entered into a partnership with Adapt Pharma to manufacture the product, Narcan. The FDA approved Narcan nasal spray in November, 2015. Emergent Biosolutions purchased Adapt Pharma in 2018.
In January 2019, the FDA initiated a policy that allows the distribution of naloxone over-the-counter through the use of consumer-friendly labels that Emergent Biosolutions uses in delivering Narcan to consumers. Emergent is required by the FDA to make certain that the product-specific parts of the labels are understood by consumers. By 2019, seven states - California, Virginia, Arizona, Ohio, Washington, Vermont and Rhode Island – required physicians to provide patients who receive opioid prescriptions (e.g., as a pain killer) to co-prescribe or, at minimum, offer Narcan to high risk patients. Many doctors consider this practice an opportunity to initiate a discussion between health care providers and patients about the dangers and risks of opioid pain medication.
Throughout the US, Narcan and naloxone have been made available OTC in 41 states; exceptions are Delaware, Hawaii, Kansas, Maine, Michigan, Nebraska, Oklahoma, South Dakota and Wyoming. The drug can be found in major retailers like CVS, Walgreens, Walmart and Kroger, as well as independent pharmacies. Many states offer lists of retailers where Narcan can be purchased. Narcan is covered by many health insurance plans.
Emergent BioSolutions was founded on September 5, 1998, under the name BioPort, and renamed Emergent BioSolutions in 2004. At the time, the Michigan Department of Public Health, though its Michigan Biologics Products Institute, owned an anthrax vaccine manufacturing facility in Lansing, Michigan. BioPort purchased the facility and the rights to manufacture the vaccine for the U.S. military.
In 2000, operating as Bioport, the company was the subject of Congressional hearings and FDA action (official action indicated (OAI) and voluntary action indicated (VAI)).  After the 2001 anthrax attacks that caused the deaths of five Americans and made 17 others ill, Bioport began providing its anthrax vaccine to US biodefense agencies.
Emergent became a publicly traded company in 2006, with its stock trading on the New York Stock Exchange under the symbol EBS.
Mergers, acquisitions and joint ventures
In June 2012, Emergent, along with Novartis and the Texas A&M University System was selected by the U.S. Department of Health and Human Services as one of the three Centers for Innovation in Advanced Development and Manufacturing. The public-private partnership granted Emergent $163 million over eight years to assist in the development of countermeasures for health, nuclear and radiological epidemics. The purpose is to produce medical countermeasures in the event of a national pandemic. Emergent's facility is located in Maryland and the company expects the site to be operational by the year 2020.
The company purchased Winnipeg, Manitoba's Cangene Corporation in 2013. Cangene's leading product is WinRho, which treats the blood disease immune thrombocytopenic purpura, as well as hemolytic disease of the newborn. Cangene also produces pharmaceuticals that treat Hepatitis B and varicella (chickenpox).
On June 27, 2016, the US Biomedical Advanced Research and Development Authority contracted with Emergent Biosolutions to develop a vaccine for the Zika virus. The contract is spread out over 30 months and is worth around $22 million. The vaccine could reach stage-one clinical trials by early 2017. As of the end of June 2016, 60 countries and territories had reported transmission of the Zika virus from mosquitoes. Emergent could become the first company to develop a vaccine for the virus.
Emergent spun off its biosciences division in August 2016, forming a new company, Aptevo Therapeutics in Seattle, WA.The new company continues its focus on developing treatments for cancer and blood diseases using its technology of dual-ended molecules that assault cancer cells, each end attacking the cancer in a different way. Aptevo had four products available at its inception.
In December 2016, Health Canada approved the purchase of Emergent's new botulism antitoxin called Botulism Antitoxin Heptavalent (BAT). The CDC and Public Health Agency of Canada both identified botulism, a type of food poisoning, as a likely biological threat. Emergent already has a ten-year contract with the Canadian military and national health service to supply BAT that began in 2012. Emergent also provides BAT to the U.S. Strategic National Stockpile. BAT was first licensed in the U.S. in 2013 and is the only botulism antitoxin available in the U.S. for naturally-occurring cases of non-infant botulism.
On March 31, 2017, Emergent signed a modification to its contract with BARDA to "manufacture and store bulk drug substance for its botulism antitoxin, BAT." The contract is valued at approximately $53 million for five years. The contract modification was technical in nature; it allows Emergent to file and deliver the final drug product to the Strategic National Stockpile in the future.
Soligenix Inc. and Emergent agreed to establish a “commercially viable production technology” for the development of RiVax, a potential vaccine aimed to protect against ricin exposure. Currently, there are no treatments for ricin poisoning that have been proven effective. Soligenix is a late-stage biopharmaceutical company that specializes in the development of treatments for rare diseases. A product of castor oil production, the ricin toxin can be a useful biological weapon due to its extreme potency, stability, and accessibility. The National Institute of Allergy and Infectious Diseases funded the development of RiVax costing an estimated $24.7 million. The organization also financially backed the contract between Emergent and Soligenix. Most of the work will be conducted in Baltimore, Maryland, at Emergent's manufacturing facility. An expansion of the Baltimore plant, finished in 2017, had $163 million in funding from the U.S. government.
In 2017, the company purchased the ACAM2000 (smallpox vaccinia) Vaccine, the only FDA-approved (2007)vaccine for active immunization against smallpox for those at a medical high risk of contracting the disease, from Sanofi Pasteur. Two years later, the Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services, has signed a contract with the company worth an estimated US$2.8 billion for the company to provide ACAM2000 over a ten-year period.
In 2018, Emergent acquired Adapt Pharma, the manufacturer of Narcan (naloxone), a widely used nasal spray opioid-overdose antidote, for $735 million. Adapt is headquartered in Dublin, Ireland, and operates from Radnor, PA.
Emergent purchased (also in 2018) the specialty vaccine manufacturer PaxVax, whose product line includes FDA-approved typhoid vaccine Vivotif and cholera vaccine Vaxchora, from its owner, Cerebus Capital Management, a private equity fund. Vaxchora is the only oral vaccine against cholera approved by the FDA in the US. The acquisition also includes rights to vaccines in development. One of these vaccines is being tested as a prophylactic against the acute-respiratory disease adenovirus. Another is focused on the chikungunya virus which is transmitted by mosquitoes. The transaction provides Emergent with a Swiss R&D facility.
Robert G Kramer Sr. became the company's president and CEO April 1, 2019. Prior to that, he was the president and chief operating officer. He has also served as Chief Operating Officer, Chief Financial Officer and other management positions within the corporation. He received his BA from Clemson University and an MBA from Western Kentucky University.
R&D, manufacturing and other products
In addition to the anthrax vaccine, Emergent BioSolutions develops and manufactures vaccines and therapeutics for the prevention or treatment of several diseases and conditions.
One of Emergent's medical countermeasure products is Reactive Skin Decontamination Lotion (RSDL), a lotion that clears and neutralizes chemical warfare agents. The product, used internationally, was tested in a study conducted by the US Army Medical Research Institute of Chemical Defense, where RSDL was found to provide superior protection against soman when decontamination was commenced within three minutes of exposure. RSDL is made of the chemicals Dekon 139 2,3 butanedione monoxime (DAM). According to the Chemical Hazards Emergency Medical Management office within the United States Department of Health and Human Services, "RSDL is used as a medical device for the decontamination of skin exposed to chemical warfare agents such as sulfur mustard, VX, VR and certain biological toxins." As of September 2017, RSDL is available to the regular public. Previously, it was only available to the military.
The United States Department of Defense in September 2017 awarded the company a contract to supply the RSDL kit (RSDL) to the military. The contract is for five years and is worth $171 million. The RSDL lotion protects people's skin from various chemical warfare agents. The product contains a sponge that is filled with the decontamination lotion in and impermeable packet. When applied to the skin, the lotion reacts with the agent on the skin and quickly neutralizes it so that it becomes non-toxic.
The Medical CBRN (Chemical, Biological, Radiological and Nuclear) Defense Consortium, a DOD initiative within its Joint Program Executive Office for Chemical and Biological Defense has awarded the company US$20 million to develop an auto-injector to administer diazepam. The injection is designed to reverse the effects of nerve agents in military or chemical terrorism situations. The investment supports R&D, manufacturing and negotiating the approval process with the US FDA.
During the COVID-19 pandemic, the company teamed with Novavax Inc., a bio-technology company also based in Gaithersburg, MD., in the development and manufacture of a vaccine for Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus which causes COVID-19. Emergent will produce the vaccine in one of its Maryland facilities based on technology developed by Novavax. Emergent petitioned the federal government's Biomedical Advanced Research and Development Authority (BARDA) to be chosen for the project.
Johnson & Johnson collaboration
The company also signed a $135 million deal with Johnson & Johnson to provide and reserve manufacturing capacity for J&J's experimental COVID-19 vaccine candidate. Human testing began in 2020. In February 2021, Johnson & Johnson petitioned US regulators for an authorization for emergency use of the company’s COVID-19 vaccine. J&J’s vaccine uses the virus (also a coronavirus) of the common cold to deliver a gene from the coronavirus (SARS-CoV-2) that provokes a person’s immune system to engage and defeat the disease. The company’s clinical trials had demonstrated the J&J vaccine was 66% effective in preventing COVID. In US trials, the same vaccine was 72% effective. If approved, the vaccine would be available for distribution within weeks. Emergent’s manufacturing facility in East Baltimore MD, built with the support of the US government before the coronavirus pandemic, was designed and constructed to make large aggregates of intricate, efficacious vaccines and therapies. In January 2021, the company had tens of millions of doses of the J&J vaccine manufactured and stockpiled, ready for distribution after FDA authorization for emergency use. The complex also is manufacturing large quantities of the Astrazeneca vaccine.
In June 2020, Cambridge UK-based pharmaceutical developer and manufacturer, AstraZeneca, initiated a $174 million (US) agreement with the company to help develop and produce 300 million doses of COVID-19 vaccine promised to be administered in the United States. Co-developed with the University of Oxford, the vaccine is among the first to begin mid-stage trials. AstraZeneca had also signed a previous agreement with Emergent for $87 million (US) naming Emergent a development partner for the vaccine, which will be manufactured at the company's Bayview plant in Baltimore MD, which the US Department of Health and Human Services has designated a center for rapid manufacturing of vaccines and other treatments in large quantities. The UK government approved Astrazenica’s vaccine in December 2020; Emergent’s facility is currently producing millions of doses, awaiting approval from the FDA for distribution in the US.
Mt. Sinai Health System collaboration
The company joined forces with New York City's Mount Sinai Health System and ImmunoTek Bio Centers (New Orleans LA) to research, develop, conduct clinical trials, and manufacture COVID-HIG, hyperimmune globulin, also known as polyclonal antibodies, a concentrated antibody made from plasma acquired from individuals infected with and recovered from COVID-19. The research is designed to determine whether COVID-HIG could protect people at higher risk of exposure and infection (like health care and military personnel) and therefore limit the spread of the infection. The initial study is funded by a $34.6 million (US) grant from the US Dept. of Defense and the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND).
Emergent Biosolutions was among many companies giving financial support to delegations at both major party political conventions in the summer of 2016, a practice that "watchdog groups have raised concerns about ... as corporate donors — skittish about Republican nominee Donald J. Trump — have sought new and less overt ways to give money and gain influence".
In October 2018, the company donated two doses of Narcan nasal spray to all 16,568 libraries in the US. Emergent had previously donated 20,000 doses to 4,700 universities in the US in 2017. It later expanded this donation to all US high schools as well. Additionally, the company donated free Narcan kits to 2,700 YMCAs across the US. Narcan and naloxone are offered at major drug retailers like Walgreens and CVS in many states without a prescription.
Emergent Biosolutions PAC donated tens of thousands of dollars in 2020 to both Republicans and Democrats from Joe Biden and Dick Durban to Andy Harris and Mitch McConnell. The contributions were directed to a majority of Democrats, but the amount donated favored the Republicans.
- Anthrax attacks of 2001
- Anthrax toxin
- Anthrax Vaccine Immunization Program
- List of pharmaceutical companies
- List of vaccine topics
- Pharmaceutical industry
- Claybaugh, Jeff (30 August 2018). "Gaithersburg company buys Narcan maker". WTOP News Radio. Washington DC: Hubbard Radio. Retrieved 27 March 2019.
- "Annual Financials for Emergent Biosolutions". Marketwatch, inc. Retrieved 11 June 2019.
- Shapiro, Andy (29 May 2008). "Md. firm to buy Protein Sciences". New Haven Register.
- "Lansing laboratory may begin anthrax vaccine shipments". The Michigan Daily. 23 January 2002. Retrieved 19 March 2015.
- "Emergent BioSolutions CEO joins board of U.S. Chamber of Commerce". The Washington Business Journal. 13 June 2011. Retrieved 19 March 2015.
- Overly, Steven (21 December 2011). "Emergent CEO to step down in 2012". The Washington Post. Retrieved 19 March 2015.
- Eckert, Barton (21 December 2011). "Emergent BioSolutions Fuad El-Hibri to retire as CEO". The Washington Business Journal. Retrieved 19 March 2015.
- \Kevin James Shay (30 March 2012). "Emergent's Fuad El-Hibri, an entrepreneur at heart". Gazette. Archived from the original on 1 August 2013. Retrieved 19 March 2015.
- Meyer Weiss, Martin; Weiss, Peter D.; Weiss, Joseph B. (November 2007). "Anthrax Vaccine and Public Health Policy". American Journal of Public Health. American Public Health Association. 97 (11): 1945–1951. doi:10.2105/AJPH.2006.102749. ISSN 1541-0048. PMC 2040369. PMID 17901434.
- Echols, Tucker (14 July 2010). "Emergent BioSolutions wins $107M HHS contract". Washington Business Journal.
- Lauerman, John (30 September 2008). "Emergent's Anthrax Vaccine Effective With Fewer Doses in Study". Bloomberg. Retrieved 11 July 2011.
- "Emergent BioSolutions Gets FDA Nod For Anthrax Vaccine supplemental BLA – Update", RTT News, December 19, 2008. Retrieved August 13, 2013.
- United States Food and Drug Administration (23 November 2015). "Vaccines, Blood and Biologics". US Food & Drug Administration. Washington DC. Retrieved 27 March 2019.
- "Paul Erlich Institute Approval". PEI.de. Langen, Hesse, Germany: Paul Erlich Institute. 24 June 2013.
- Clabaugh, Jeff (24 June 2011). "Emergent gets entry to Singapore". Washington Business Journal. Retrieved 22 July 2011.
- "Local Briefing". The Washington Post. 13 February 2009. Retrieved 11 July 2011.
- Kovaleski, Dave (18 December 2018). "Health Canada approves Emergent BioSolutions' new anthrax vaccine". Homeland Preparedness News. Washington DC. Retrieved 27 March 2019.
- Bryan, Cohen (21 April 2014). "Emergent BioSolutions' BioThrax receives orphan drug designation for PEP". BioPrepWatch. Chicago, Illinois. Retrieved 1 May 2014.
- "Emergent BioSolutions Receives Orphan Drug Designation for BioThrax for Post-Exposure Prophylaxis of Anthrax Disease". MarketWatch.com. Wall Street Journal. Dow Jones & Company. 21 April 2014. Retrieved 1 May 2014.
- PropThink, P. (2014). "Emergent BioSolutions Is Building An Enviable BioDefense Portfolio". Seeking Alpha. Retrieved 1 May 2014.
- "Emergent Biosolutions secures $911 mln contract to supply anthrax vaccines to Strategic National Stockpile". Homeland Preparedness News. 2016-12-09. Retrieved 2016-12-14.
- Lovelace, Jr., Berkeley (2016-06-21). "Emergent BioSolutions moves closer to facility approval for anthrax vaccine". CNBC. Retrieved 2016-06-24.
- Srivastava, Benjamin; Gold, Mark (March 2018). "Beyond Supply: How We Must Tackle the Opioid Epidemic". Mayo Clinic Proceedings. 93 (3): 269–272. doi:10.1016/j.mayocp.2018.01.018. PMID 29502558.
- Voelker, Rebecca (20 November 2018). "Will Naloxone Become Available OTC?". Journal of the American Medical Association. 320 (19): 1970. doi:10.1001/jama.2018.17836. PMID 30458477.
- "Molecule of the week: Naloxone". ACS.org. American Chemical Society. 23 May 2016. Retrieved 1 July 2019.
- Halford, Beverly (16 May 2016). "Improving an old tool to prevent opioid overdoses". Chemical and Engineering News. 94 (20): 34–38. Retrieved 1 July 2019.
- Hopkins, Jared (28 August 2018). "Narcan maker Adapt to be acquired by Emergent Biosolutions". Bloomberg.com. Retrieved 1 July 2019.
- Edney, Anna (17 January 2019). "The FDA Is Trying to Make It Easier for Drug Companies to Provide Over-the-Counter Opioid Overdose Antidote". Time Magazine. Retrieved 1 July 2019.
- Ostrov, Barbara Feder (27 February 2019). "More States Say Doctors Must Offer Overdose Reversal Drug Along With Opioids". Kaiser Health News. San Francisco CA: Kaiser Family Foundation.
- DeMio, Terry (6 April 2018). "To save lives, the surgeon general says get the opioid antidote naloxone. Here's what to do". USA Today. McLean VA: Gannett Company.
- Tinder, Paul (10 November 2009). "Emergent BioSolutions appoints Jackson as chief scientific officer". Vaccine News Daily. Retrieved 30 April 2014.
- "Emergent acquires vaccine company". BIOTECH Patent News. 1 June 2005. ISSN 0898-2813.
- "Emergent BioSolutions mit verstärkter Präsenz in Deutschland". Bionity.com (in German). Bionity. August 7, 2006. Retrieved 30 April 2014.
- "Avanir Divests Anthrax mAb Program to Emergent BioSolutions in Deal Worth $1.75M". Genetic Engineering & Biotechnology News. 6 March 2008. Retrieved 12 October 2011.
- "VaxGen sells anthrax vaccine candidate to Emergent BioSolutions". Forbes. Thomson Reuters. 5 May 2008. Retrieved 11 July 2011.
- "VaxGen wraps up sale of anthrax assets". San Francisco Business Times. 5 May 2008. Retrieved 11 July 2011.
- "Emergent BioSolutions Completes Acquisition Of Trubion Pharmaceuticals". The Street. 28 October 2010. Retrieved 30 April 2014.
- Cohen, Bryan (6 August 2013). "Emergent BioSolutions closes on acquisition of Bracco Diagnostics division". Vaccine News Daily. Retrieved 1 May 2014.
- "Emergent BioSolutions Closes on Its Acquisition of Healthcare Protective Products Division from Bracco Diagnostics Inc". Yahoo! Finance. 2 August 2013. Retrieved 1 May 2014.
- "EMERGENT BIOSOLUTIONS INC (EBS:New York): Company Description". Bloomberg Businessweek. Retrieved 28 September 2012.
- "Lansing laboratory may begin anthrax vaccine shipments". The Michigan Daily. 23 January 2002. Retrieved 30 April 2014.
- Williams, Thomas D. (18 May 2001). "Shays: Pentagon Acted Inappropriately". The Hartford Courant. Retrieved 30 April 2014.
- Committee on Government Reform Hearings for the US House of Representatives October 3rd and 11th, 2000 | url=http://www.protectingourguardians.org/docs/accountability_for_DoD,_BioPort,_FDA_by_Cong._gov_reform_comm.pdf
- "Bioport Corporation, Lansing, MI, FDA 483, dated 10/10-26/2000; (18 pages)" | url=https://www.fda.gov/media/70841
- "How a company cashed in on anthrax" by Bob Evans December 5, 2005 Daily Press.com | url=https://www.dailypress.com/news/dp-anth-day4-bioportdec06-story.html
- Congressional Report 106-556 "The Department of Defense Anthrax Vaccine Immunization Program: Unproven Force Protection." March 9, 2000 | uurl=https://www.congress.gov/congressional-report/106th-congress/house-report/556/1
- Gregg, Aaron (12 August 2018). "Emergent Biosolutions to acquire cholera and typhoid vaccines in $270 million deal". Washington Post. Washington DC: Nash Holdings.
- "History". Emergent BioSolutions. Retrieved 1 May 2014.
- "Emergent licenses flu vaccine for new federal biodefense center". Gazette.net. 4 January 2013. Archived from the original on 1 August 2013. Retrieved 25 January 2013.
- Sievers, Lisa (15 April 2014). "First of three pandemic manufacturing sites could be ready by 2016". Chicago, Illinois. Retrieved 1 May 2014.
- Overly, Steven (11 December 2013). "Emergent BioSolutions pays $222M to acquire life sciences firm Cangene Corp". Wall Street Journal. Dow Jones. Retrieved 8 May 2019.
- Leong, Tracey (2016-07-10). "Md. Company To Develop Early-Stage Zika Vaccine". CBS-Baltimore. Retrieved 2016-07-13.
- "Emergent BioSolutions receives BARDA order to develop, manufacture Zika vaccine". Homeland Preparedness News. 2016-06-27. Retrieved 2016-07-13.
- Gregg, Aaron (2016-06-27). "Emergent BioSolutions wins contract to develop Zika vaccine". Washington Post. Retrieved 2016-07-13.
- Lerman, Rachel (1 August 2016). "Seattle biotech Aptevo Therapeutics spins off from parent as public company". Seattle Times.
- "Emergent BioSolutions Receives Health Canada Approval for Botulism Antitoxin". Investors.emergentbiosolutions.com. Emergent Biosolutions. 2016-12-06. Retrieved 2017-01-11.
- "Health Canada approves Emergent BioSolutions' botulism antitoxin". Homeland Preparedness News. 2016-12-13. Retrieved 2017-01-11.
- "Emergent Biosolutions modifies contract with BARDA for supplying botulism antitoxin to national stockpile". Homeland Preparedness News. Washington DC: Macallan Communications. 31 March 2017. Retrieved 7 April 2019.
- "Soligenix, Emergent Biosolutions extend development agreement for RiVax drug substance protein antigen". Homeland Preparedness News. 2017-01-05. Retrieved 2017-01-20.
- Willman, David, "Federal vaccine development sites ill-suited to counter covid-19 epidemic", Washington Post, March 15, 2020. Retrieved 03-15-2020.
- "Emergent Buys Sanofi Pasteur's Smallpox Vaccine for Up-to-$125M". Genetic Engineering and Biotechnology News. New Rochelle NY: Mary Anne Liebert, Inc. 2017-07-14. Retrieved 13 March 2019.
- Gilgore, Sara (3 September 2019). "Emergent lands federal contract for smallpox vaccine potentially worth more than $2B". Washington Business Journal. Washington DC: American City Business Journals.
- Hopkins, Jared (28 August 2018). "Narcan Maker Adapt to Be Acquired by Emergent BioSolutions". Bloomberg.com. New York, NY: Bloomberg Finance LP. Retrieved 27 February 2019.
- Green, Aaron (12 August 2018). "Emergent BioSolutions to acquire cholera and typhoid vaccines in $270 million deal". Washington Post. Retrieved 1 May 2019.
- "Executive Profile and Biography". Bloomberg Research. Retrieved 6 April 2019.
- "Emergent BioSolutions Secures Orphan Drug Designation for Its Investigational Monoclonal Antibody for the Treatment of Inhalation Anthrax". Health & Beauty Close-Up. 9 November 2010.
- Braue Jr., Ernest (20 October 2010). "Efficacy studies of Reactive Skin Decontamination Lotion". Cutaneous and Ocular Toxicology. London UK: Taylor and Francis. 30 (1): 29–37. doi:10.3109/15569527.2010.515281. PMID 20964500. S2CID 207607970.
- "Reactive Skin Decontamination Lotion (RSDL) - Medical Countermeasures Database - CHEMM". Chemm.nlm.nih.gov. Retrieved 2 June 2019.
- Riley, Kim (2017-09-12). "Emergent BioSolutions launches chemical warfare decontamination lotion to civilian market". Homeland Preparedness News. Retrieved 2017-09-18.
- Murtha, Alex (25 September 2017). "Emergent BioSolutions awards renewed five-year contract to supply chemical agent-neutralizing lotion to US military". Homeland Preparedness News.
- Gilgore, Sara (26 September 2019). "Emergent lands $20M contract to develop chemical weapon antidote". Washington Business Journal. Washington DC: American City Business Journals.
- "Maryland plays an outsized role in worldwide hunt for a coronavirus vaccine". Washington Post. Retrieved 2020-05-08.
- Butler, Cody (9 March 2020). "Lansing company looking to help develop coronavirus vaccine". WILX Television. Lansing MI: Gray Television.
- "J&J strikes deal with Emergent BioSolutions on coronavirus vaccine manufacturing". Reuters. 2020-04-23. Retrieved 2020-05-08.
- Loftus, Peter (5 February 2021). "Johnson & Johnson Asks U.S. Regulators for Emergency Approval of Its Covid-19 Vaccine". The Wall Street Journal. New York, NY: Dow Jones & Co.
- Cohn, Meredith (29 January 2021). "A plant in East Baltimore is making millions of doses of coronavirus vaccines. But they still have to be approved". Baltimore Sun. Baltimore MD: Tribune Publishing Group.
- Roy, Trisha (27 July 2020). "Emergent signs $174 million deal to make AstraZeneca's potential COVID-19 vaccine". Reuters. London UK: Thomson Reuters.
- Pope, Chris (5 February 2021). "Is it time to approve the Astrazeneca vaccine?". City Journal. New York NY: Manhattan Institute.
- "Emergent Biosolutions, Candidates: COVID – HIG, COVID-EIG". Genetic Engineering and Biotechnology News. New Rochelle NY: Mary Ann Liebert Inc. 18 May 2020.
- Fritze, John (2016-07-20). "State issues, money follow delegates to conventions". The Baltimore Sun. Retrieved 2016-08-01.
- Inklebarger, Timothy (24 October 2018). "Company to Supply Free Narcan to Libraries". American Libraries. Chicago: American Library Association. Retrieved 29 April 2019.
- Ducharme, Jamie (25 October 2018). "Every U.S. Public Library and YMCA Will Soon Get Narcan for Free". Time Magazine. New York NY: Mark Benioff.
- "Emergent Biosolutions". Open Secrets.com. Washington DC: The Center for Responsive Politics. Retrieved 14 January 2021.